BioNTech SE (BNTX)
Pre-market:
| Previous close | 158.59 |
| Open | 160.50 |
| Bid | 159.69 x 1000 |
| Ask | 161.85 x 900 |
| Day's range | 158.60 - 161.60 |
| 52-week range | 117.08 - 388.00 |
| Volume | |
| Avg. volume | 1,097,566 |
| Market cap | 38.915B |
| Beta (5Y monthly) | -0.08 |
| PE ratio (TTM) | 3.44 |
| EPS (TTM) | 46.63 |
| Earnings date | 07 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 02 June 2022 |
| 1y target est | 240.07 |
- Yahoo Finance
Vaxxinity CEO on COVID: The market isn't going away and it's going to be a massive commercial opportunity
Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.
- Motley Fool
Is This Battered Growth Stock Still a Buy After Its Latest Stumble?
After reporting worse than anticipated second-quarter earnings on Aug. 8, shares of BioNTech (NASDAQ: BNTX) are tumbling, deepening the stock's decline to 65% over the last 12 months. The culprit is the biotech's lackluster sales of Comirnaty, its coronavirus vaccine developed in conjunction with Pfizer.
- Motley Fool
Why BioNTech Was Tumbling Again Today
This isn't shaping up to be a banner week for BioNTech (NASDAQ: BNTX). The bellwether coronavirus stock took it on the chin Monday and was being similarly battered by investors Tuesday because of post-earnings analyst price target cuts. Following second-quarter results that disappointed many investors, several analysts recalibrated their takes on BioNTech stock Tuesday.
